Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells
- PMID: 12702591
Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells
Abstract
Progression of prostate cancer to androgen-refractory disease is correlated with increased expression of growth factors and receptors capable of establishing autocrine and/or paracrine growth-stimulatory loops. Many of these growth factor receptors engage Ras as part of their normal signaling activities, raising the possibility that activation of endogenous c-Ras could be a common mechanism for prostate cancer progression. Here we demonstrate that inducible expression of a dominant negative form of Ras restores androgen sensitivity to a hormone-refractory prostate cancer cell line. We show that expression of RasN17 in the hormone-refractory C4-2 cell line enhances in vitro sensitivity to the growth-inhibitory action of the antiandrogen Casodex and inhibits anchorage-independent cell growth. Moreover, although induction of RasN17 by itself has no observable effect on the growth of C4-2 xenografts in intact male mice, it restores androgen dependence to the C4-2 xenografts so that they dramatically regress after surgical androgen ablation.
Similar articles
-
Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells.Cancer Res. 2003 Apr 15;63(8):1981-9. Cancer Res. 2003. PMID: 12702592
-
Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.Cancer Res. 2003 Sep 1;63(17):5622-8. Cancer Res. 2003. PMID: 14500404
-
PC-1/PrLZ contributes to malignant progression in prostate cancer.Cancer Res. 2007 Sep 15;67(18):8906-13. doi: 10.1158/0008-5472.CAN-06-4214. Cancer Res. 2007. PMID: 17875733
-
[Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches].Urologe A. 2008 Mar;47(3):314-25. doi: 10.1007/s00120-008-1637-1. Urologe A. 2008. PMID: 18273598 Review. German.
-
RAS pathways in prostate cancer - mediators of hormone resistance?Curr Cancer Drug Targets. 2010 Dec;10(8):834-9. doi: 10.2174/156800910793358005. Curr Cancer Drug Targets. 2010. PMID: 20718703 Review.
Cited by
-
Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression.Oncotarget. 2015 Feb 10;6(4):1900-19. doi: 10.18632/oncotarget.2953. Oncotarget. 2015. PMID: 25595909 Free PMC article. Review.
-
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):E3506-15. doi: 10.1073/pnas.1303558110. Epub 2013 Aug 5. Proc Natl Acad Sci U S A. 2013. PMID: 23918374 Free PMC article.
-
Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.Prostate Cancer. 2013;2013:920612. doi: 10.1155/2013/920612. Epub 2013 Apr 29. Prostate Cancer. 2013. PMID: 23738079 Free PMC article.
-
Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones.Nat Commun. 2022 Sep 17;13(1):5475. doi: 10.1038/s41467-022-33069-3. Nat Commun. 2022. PMID: 36115838 Free PMC article.
-
AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion.Exp Cell Res. 2013 Jul 15;319(12):1732-1743. doi: 10.1016/j.yexcr.2013.05.008. Epub 2013 May 20. Exp Cell Res. 2013. PMID: 23701950 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous